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Therapeutic improvements and epidemiologic changes in head and neck cancer (HNC) over the last three decades
have led to increased numbers of survivors, resulting in greater need for continuing management of oral and
dental health in this population. Generally, the HNC patient oral health needs are complex, requiring
multidisciplinary collaboration among oncologists and dental professionals with special knowledge and training in
the field of oral oncology. In this review, we focus on the impact of cancer treatment on oral health, and the oral
care protocols recommended prior to, during and after cancer therapy. The management of oral complications
such as mucositis, pain, infection, salivary function, taste and dental needs are briefly reviewed. Other complications
and their management, including osteonecrosis of the jaw and recurrent/new primary malignancies are also
described. This review offers clinical protocols and information for medical providers to assist in understanding oral
complications and their management in HNC patients and survivors, and their oral and dental health care needs.
Oral and dental care is impacted by the patient’s initial oral and dental status, as well as the specific cancer
location, type, and its treatment; thus, close communication between the dental professional and the oncology
team is required for appropriate therapy.
Keywords: Cancer treatment protocol, Cancer pre-treatment protocol, Oral hygiene, Oral complication
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More than 600,000 cases of HNC are diagnosed each
year worldwide. With evolving etiologies and advances
in treatment, HNC survival has improved in recent de-
cades and the population of HNC survivors continues to
grow [1]. This increasing number of survivors raises
additional challenges, particularly in the management of
those patients who have complex medical, oral/dental,
and psychosocial needs. Management of the oral compli-
cations in this population typically requires multidiscip-
linary collaboration among different professionals and
healthcare providers, including head and neck surgeons,
medical oncologists, radiation oncologists, and dental
professionals with special knowledge and training in the
field of oral oncology.
HNC may present with oral manifestations, which ne-
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the mouth both directly through cytotoxicity, and indir-
ectly through the effects on immune function or other
systemic side effects. Common oral complications in-
clude pain, mucositis, salivary gland dysfunction, taste
loss/change, infections, dysphagia, fibrosis, soft tissue
and/or bone necrosis, exacerbation of dental and peri-
odontal diseases, and recurrent or secondary malignancy
[4]. The incidence and severity of oral complications are
affected by cancer treatment modality(s) used, anatomic
location and stage of the cancer, extent of oral or dental
diseases prior to treatment, comorbidities and genetic
risk, oral hygiene and nutrition [5]. To effectively pre-
vent as well as treat oral complications, dental profes-
sionals play important roles prior to, during and
following active cancer treatment [6].
For HNC survivors, it is generally recognized that
trained/experienced dental professionals serve as integral
components of the multidisciplinary oncology team. These
dental professionals can play a role in prevention of oral
complications through patient education (improve oralle is distributed under the terms of the Creative Commons Attribution 4.0
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use), treatment of dental disease, prophylactic strategies
and treatment of oral complications, and early detection of
oral malignancy in high-risk patients [7]. The related refer-
ral pathways are through dental and medical specialists
with oncology experience [8]. This review focuses on the
role of dental health care providers, and protocols of oral
care in HNC patients.
Head and neck cancer treatment and its impact
on the oral cavity
All treatment modalities for HNC produce oral complica-
tions, including surgery (e.g. mutilation and physiologic
changes), radiation therapy (e.g. mucositis, dysphagia, hypo-
salivation, osteoradionecrosis), and neoadjuvant, adjuvant
and/or concurrent chemotherapy (e.g. mucositis, taste
changes, immune suppression) [9]. Additionally, newer tar-
geted therapies may also result in oral mucosal complica-
tions [10, 11]. These medications include epidermal growth
factor inhibitors, which cause erythematous mucosal reac-
tions; tyrosine kinase inhibitors and mammalian target of
rapamycin (mTOR) inhibitors, both of which may cause
isolated aphthous-like lesions; and emerging immunother-
apies, which may induce lichenoid reactions [12]. Given the
commonality of oral complications of therapy, pre-
treatment oral conditions may affect therapeutic options se-
lected for some patients [2]. Additionally, the long-term
oral sequelae of these treatments require oral and dental
follow-up and fastidious long-term oral care.
Oncologists need to recognize the importance of pre-
treatment dental care, and use available resources to effect-
ively address oral needs [13]. For improved outcomes, it is
imperative that a thorough oral assessment, implementa-
tion of basic oral care protocols, management of pre-
existing dental conditions, and prevention and manage-
ment of emerging oral complications be completed before
HNC treatment. This is best accomplished by integrated
teams with oncology-trained/experienced dental providers
who provide timely dental treatment and preventive proto-
cols that do not disrupt cancer therapy.
The following sections provide a summary of evidence-
based guidelines related to oral/dental management in
HNC patients, with the goal of improving health out-
comes and enhancing long-term quality of life.
Before HNC therapy
It is important to be aware that some practicing dentists
may have limited experience in care of the oncology
patient, and that dental professionals with oncology experi-
ence may be required to identify and manage oral condi-
tions and diseases in HNC patients [14]. According to the
Multinational Association of Supportive Care in Cancer/
International Society of Oral Oncology (MASCC/ISOO)
guidelines, thorough basic oral care is recommended to allcancer patients for control of bacterial flora and reduction
of inflammatory and/or infectious complications [15, 16].
Oral hygiene recommendations are shown in Table 1.
HNC patients should receive a comprehensive oral as-
sessment prior to any cancer treatment, as soon as pos-
sible after diagnosis, and ideally, within 2 to 3 weeks
prior to beginning cytotoxic therapy, in order to allow
time for healing if surgical dental procedures are indi-
cated [17–19]. The assessment should include full peri-
odontal examination, radiographic examination, salivary
gland functional assessment, and jaw range of motion
measurement. Other treatments, such as non-surgical
dental needs and stabilizing dental conditions can be
completed as needed, or postponed until after cancer
therapy, if deemed elective [20, 21].
Individual HNC patients should be managed according
to cancer therapy-specific pre-treatment dental protocols
[22]. Absence of symptomatic and occult oral disease is
the desired goal, and elimination of acute and chronic in-
fections that may require future surgical care is indicated
prior to cancer therapy. Oral tissues within the high dose
radiation fields must receive particular attention, as post-
radiation surgery in this region may be risky. Custom oral
devices (positioning/opening devices, midline blocks or
anti-scatter trays) may be prescribed to minimize radiation
exposure to oral structures unaffected by cancer and to
assist in tissue positioning in order to support radiation
exposure to movable tissues on a repeated basis. Compro-
mises in timing and extent of dental treatment may be ne-
cessary, particularly when tumor burden is excessive, but
generally, the healthier the mouth, the better the odds for
good outcomes [21, 22].
During HNC treatment
It is essential that oncologists and other physicians in-
volved in cancer care communicate with trained dental
professionals in complex and unique cancer cases [23]
so that necessary treatment is provided in timely fashion,
unnecessary treatment is avoided, and preventive proto-
cols are instituted. Even though cancer patients may be
inclined to discontinue oral hygiene due to discomfort,
the avoidance of basic hygiene results in increased mi-
crobial loads, gingival/oral inflammation and risk of in-
fections. Thus, maintenance of oral hygiene should be
encouraged. If oral hygiene is compromised during can-
cer treatment, the daily use of aqueous chlorhexidine
0.12 % solution can control the overall microbial load,
including fungal and yeast overgrowth [24]. Devices built
for prophylactic purposes (midline blocks, custom trays,
etc.), must be used according to protocol.
Oral pain, predominantly due to mucositis, is one of the
major symptoms in radiation therapy with or without
chemotherapy. The biology of mucositis has been described
and is leading to study of interventions based on the
Table 1 Oral care prior to and post cancer treatment in head and neck cancer survivors
Pre – Cancer Treatment o Pre-treatment assessment 2–3 weeks prior to cancer therapy
o Comprehensive head and neck, oral mucosa, dental and periodontal examination
o Radiographs to assess dental and periodontal status
o Baseline jaw range of motion (interincisal opening), baseline resting and stimulated saliva
o Advanced caries, advanced periodontal disease: definitive treatment may require surgery
with goal of 1–2 weeks of healing time
o Periodontal debridement maintenance; oral hygiene instruction
o Custom fluoride carriers, custom oral positioning devices
During Cancer Treatment o Individual treatment as cancer type and planned treatment indications
o Oral hygiene reinforced
o Small carious lesions may be treated with fluoride and/or sealants; daily fluoride applications
o Symptom management: Pain: topical analgesic and anesthetic agents; systemic analgesics;
dry mouth: hydration, oral rinses and coating agents; lip management
o Mucositis reduction: Patient education:
o Regular brushing, flossing; prosthesis cleaning
o Bland oral rinses, water based/wax or lanolin lip lubricant
o Fluoridated toothpaste; or home fluoride trays daily in high risk patients
o Soft toothbrushes; Electric or ultrasonic brushes for tolerated patients
o Super-soft brush for severe mucositis or foam brush with chlorhexidine if brushing not possible
o Dietary instruction; nutritional guidance, tobacco and alcohol avoidance
Post – Cancer Treatment o Monitoring, prevention and management of oral complications (mucositis, dry mouth,
mucosal pain, taste change, infection, dental demineralization, dental caries, periodontal
disease, soft tissue/osteonecrosis etc.)
o Checking for cancer recurrence or secondary primary cancer
o Dental caries prevention, periodontal maintenance
o Determine frequency of dental hygiene follow-up interval based on level of hyposalivation,
demineralization/caries rate and patient’s oral hygiene post-radiotherapy; patients with dry mouth,
may require hygiene and recall every 3–4 months
o Patient education
o Fluoridated toothpaste; in high risk patients home fluoride trays daily
o Good oral hygiene, soft toothbrushes or electric or ultrasonic brushes, flossing
o Maintain lubrication of mouth and lips
o Encourage non-cariogenic diet and cessation of tobacco & alcohol
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due to mucositis, MASCC/ISOO recommends topical anal-
gesic/anesthetic agents (e.g., lidocaine, benzocaine, diphen-
hydramine), or in severe cases, patient-controlled analgesia
(parenteral morphine sulphate). Study of potential preven-
tion of mucositis is ongoing, with recent suggestion for use
of low-energy laser (LLLT), which may significantly reduce
the severity and duration of mucositis [2, 14]. Medications
that affect neuropathic pain such as gabaminergic agents
(e.g. gabapentin), or tricyclic antidepressants (e.g. imipra-
mine, amitriptyline) should be considered in addition to
systemic analgesics [26]. Pain management strategies for
this group of patients are summarized in Table 2. InTable 2 Pain management Techniques in oncology (modified
from Epstein et al.; Orofacial pain in Cancer; Part II- Clinical




Adjunctive medications (eg: Anxiolytics, Anticonvulsants, Antidepressant)
Physical and rehabilitative therapy: (massage/Physiotherapy; Cold/moist
heat compresses)
Photobiomodulation/acupuncture
Psychologist support (Cognitive behavioral therapy, hypnosis)addition, dietary instruction, frequent use of saline/bicar-
bonate rinses, and good oral hygiene should be addressed.
Finally, a number of medical devices typically described as
mucosal coating agents (eg: Biotene ®, Gelclair®, Mugard ®,
Gelclair ® and others), has been cleared by the FDA but data
supporting impact on mucositis are limited and no guide-
lines have been developed by MASSC/ISOO to date.
Nevertheless, these over-the-counter coating agents may be
soothing and promote temporary oral comfort.
In addition to mucositis, acute oral/dental infection dur-
ing radiation therapy may be a cause for cancer treatment
interruptions and excess morbidity. Extractions or other
surgical procedures are not indicated during cytoreductive
therapy. Hence, the alternative to surgical treatment is
medical management, using antibiotics and analgesics that
may control, but not resolve the infection, and create add-
itional issues for the patient. Dental disease prevention
must include regular daily fluoride applications, best ap-
plied via custom-made fluoride trays; when not able to be
used (e.g. if severe mucositis develops), application by
brushing on teeth or rinse application can be substituted.
Fluoride application must be continued on a daily basis as
long as dry mouth persists. In these patients, it is also im-
portant to provide a topical calcium source for the teeth
in addition to fluoride. Special toothpastes (e.g. Enamelon
®) have been designed for this purpose.
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ment in order to support nutrition, reduce alcohol and
tobacco use, and receive optimal oral care, which are im-
portant for both oral health and effective completion of
cancer therapy [27, 28]. In addition, other factors such
as taste changes, mucosal sensitivity, and xerostomia
may negatively impact diet and nutritional intake, which
may affect oral and general health. As a consequence,
oral symptoms need attention from both oncologists and
dental professionals in order to ensure timely diagnosis
and appropriate treatment, as well as patient compliance
with treatment recommendations.
Post HNC treatment
Cytotoxic treatment-induced oral complications can be
severe, and impact not only the quality of life, but also
cancer therapy outcomes. This can be challenging, as pa-
tients are known to under-report oral complications to
their medical providers during and following cancer
therapy. HNC patients should be monitored closely to
reinforce prevention, early diagnosis and management of
late complications, and optimal oral care to prevent
these complications. Timely identification of cancer re-
currence and/or metastasis, leading to early referral is
also indicated [29]. Effective management of oral infec-
tion, residual mucositis, sensory changes (mucosal pain,
taste change/loss), reduced/altered salivation, dental and
periodontal disease, soft tissue/bone necrosis, and tem-
poromandibular joint disorders must be integral part of
post-cancer therapy care [30]. Follow-up dental visits
should be tailored and individualized based on patient
conditions. At least twice per year check-ups are recom-
mended, although an every 2–3 month schedule may be
indicated for some cases (Table 1).
Patients should be instructed in daily atraumatic tooth
brushing, bland oral rinses, flossing and fluoride gel ap-
plications, as well as management of mucositis and other
residual sequelae, based on the MASCC/ISOO evidence-
based guidelines [2, 11]. Ultrasonic or electric brushes
may be recommended, although soft or supersoft man-
ual toothbrushes are standard [31]. Prescription tooth-
paste/gel with 5000 ppm fluoride are recommended for
dentate patients, but if the patient cannot tolerate due to
mucositis, fluoride rinses may be substituted for short
periods; return to brushing with prescription toothpaste
should be conducted as soon as possible and maintained
for the duration of the patient’s dentate life.
Patients skilled at dental flossing should be instructed
to continue, avoiding trauma to the gingival tissue.
Other interdental cleaning aids may be chosen if they
are effective, and can be used atraumatically [32, 33].
Diet and supplements that are rich in carbohydrates, as
well as sucrose-sweetened medications should be
avoided, or when needed to support energy intake,should be taken with meals, and may be best after oral
hygiene is performed [34].
Management of specific oral complications
related to HNC
Mucositis
Mucositis is recognized as a critical, dose-limiting tox-
icity of current HNC cytotoxic therapy and its preva-
lence approaches 100 %. Acute signs and symptoms
typically develop during second or third week of therapy
and may continue for weeks to months following com-
pletion of treatment, particularly in those patients
treated with chemoradiation [35]. Chronic mucosal sen-
sitivity may be increased in those who experienced se-
vere acute mucosal damage [33]. Radiation-induced loss
of stem cells in the basal layer interferes with the re-
placement of cells in the superficial mucosal layers when
they are lost through normal physiologic sloughing. The
subsequent denuding of the epithelium results in muco-
sitis, which can be painful and interfere with oral intake
and nutrition. Chemotherapy can have a similar effect
on the mucosa. Patient education includes frequent use
of non-medicated bland oral rinses, possible use of film
forming, lubricating mucosal coating agents, and topical
analgesics/anesthetics as needed. Mouthwashes with al-
cohol, foods with acidic or spicy qualities, and coarse or
abrasive foods should be avoided [36, 37]. Thorough and
consistent oral hygiene is recommended.
Active research continues to evaluate novel prevention
and treatment approaches to mucositis for future clinical
application. Current management is focused on palli-
ation of symptoms with topical and systemic analgesics.
It is also important to recognize that pain due to muco-
sitis is related to tissue damage and inflammation, result-
ing in nociceptive pain, but also due to neuropathic
sensitization (neuropathic pain), which can be treated
with neurologically active medications such as gabapen-
tin and doxepin [37–41].
Oral mucosal infections – viral, bacterial and fungal
infections
Patient monitoring is critical in diagnosis of viral, bacter-
ial and fungal infections. Diagnosis can be challenging
during the period of mucositis, as there may be consid-
erable overlap in signs and symptoms of mucositis and
infection. Viral infections such as Herpes simplex virus
(HSV), and other herpes viruses are common in patients
treated with chemotherapy, while HSV reactivation is
uncommon in HNC patients treated with radiation
alone. Acyclovir and valcyclovir are considered equally
effective in HSV prevention and treatment [42, 43]. Oral
manifestations of viral infection may be more severe,
with altered presentation and a more protracted course
in cancer survivors. The more severe reactivation of
Samim et al. Cancers of the Head & Neck  (2016) 1:14 Page 5 of 7Varicella-Zoster virus (shingles) requires larger doses of
antiviral agents, which may be combined with systemic
corticosteroids.
Bacterial infection occurs most commonly in association
with dental or periodontal infection that may worsen dur-
ing cancer treatment. For suitable selections of antibiotics
(begin on an empiric basis for oral and dental infection),
bacterial culture and antibacterial sensitivity tests may be
required due to potential shifts in oral colonization, par-
ticularly in hospitalized patients, and in patients not
responding to therapy as expected [34].
Oral yeast infection, most commonly due to Candida
albicans is found in 7.5, 39.1 and 32.6 % prior to, during
and post HNC therapy, respectively [44]. Clinical pres-
entation of oropharyngeal candidiasis may be variable
and not easily recognized, presenting as white patches,
erythematous patches or plaques, as hyperplastic candid-
iasis or mixed presentation [44]. Recognition of infection
may be challenging due to multiple presentations and
overlap with other mucosal changes such as mucositis.
Other symptoms such as coated sensation in the mouth,
burning sensation and taste change can be associated
with candidiasis and should raise attention.
Topical therapy for local disease is always preferable,
but systemic antifungals may be necessary in the setting
of immune deficiency or loss of mucosal integrity. On-
cologists need to be aware that topical antifungal agents
have had inconsistent efficacy and some are high in
sugar, which reduces efficacy and increases dental caries
risk in dry mouth dentate patients. Antifungals that are
not sugar sweetened (e.g. vaginal suppositories), and oral
systemic agents are more effective [45, 46]. Furthermore,
additional fungal species with increased resistance to an-
tifungal agents are observed in cancer patients, and
therefore the principles of culture and identification of
the fungal species may be important to guide therapy,
particularly in non-responding cases [44].
Other oral complications and their management
Other oral complications in HNC survivors are common.
The key is to identify risk factors and early onset symp-
toms, and to offer referral for expert care. For example,
HNC patients receiving cytotoxic chemotherapy and
radiotherapy can have dry mouth or xerostomia that con-
tinues indefinitely due to reduced saliva production (hypo-
salivation) [47, 48]. Dry mouth is a common and
significant chronic complication and drives late oral com-
plications; some patients may accommodate to ongoing
hyposalivation over time and may report reduced or even
no symptoms. However, effects of reduced saliva on the
health of oral tissues continue. Hyposalivation manage-
ment includes assessment of saliva production, with first
approach to treatment being stimulation of any residual
function (chewing and taste stimulation, systemicsialagogues such as pilocarpine, civemiline, or bethane-
chol), and palliative topical products [49]. In addition to
reduced production of saliva, changes in the quality of sal-
iva, with thickened or viscous secretions can be challen-
ging to manage, and trials of mucolytic agents may be
considered (guaifenesin, acetyl-cysteine). Encouraging
good daily oral hygiene, frequent dental visits, and dental
fluoride and remineralization supplementation can help
counteract the changes induced by insufficient salivation.
For those patients with persisting hyposalivation, wetting
of oral surfaces, and replacement of calcium, phosphate,
and use of antimicrobial rinses have been shown to be safe
and effective in relieving symptoms of dry mouth and
minimizing infection potential. Dry mouth-associated
taste change, gastrointestinal upset, mucosal sensitivity,
inflammation and ulceration [50] significantly limit food
intake, and may lead to dietary compromise that compli-
cates nutrition and general health. Dry mouth increases
risk of dental demineralization and tooth cavitation that
can lead to rampant dental damage, increase risk for pro-
gression of periodontal disease and increase risk of osteor-
adionecrosis of the jaw (ORN). Dental sensitivity to
temperature is also associated with lower saliva secretion
and lower salivary pH. Oral burning sensation due to mu-
cosal sensitivity is associated with hyposalivation and
arises from peripheral neuropathy [2, 51]. In addition, 50–
75 % of HNC patients have dysgeusia, which contributes
to the reduction in quality of life. Radiation- and
chemotherapy-induced neuropathies are associated with
inflammation, neurotoxicity, oxidative stress, and ische-
mia, which may persist long after clinical mucositis re-
solved [52, 53].
Among other complications, ORN is a known risk fol-
lowing head and neck radiotherapy. It is associated with
dental disease and dental procedures, but can occur
spontaneously, without identified stimulus. This risk
may be increased in people on medications such as
bisphosphonates or denosumab for osteoporosis, people
with diabetes, on immunosuppressives, and in tobacco
users [54]. Prevention of ORN is the key concept and it
reinforces the need for dental stabilization before cancer
therapy, and continuing good oral/dental health in survi-
vors. Management of ORN after onset must be individu-
alized in coordinated dental and medical care.
Current treatment strategies are based on limited re-
search and clinical anecdotes and thus, should be under-
taken by experienced healthcare providers due to the
complexity of care. Hyperbaric oxygen (HBO) therapy and
use of antiseptic oral rinses, and sometimes antibiotics
when secondary infection is diagnosed, has been the med-
ical approach to therapy [55]. However, the use of HBO is
expensive and controversial and no good evidence for or
against it has been published. More recently medical
management with local infection management and
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II clinical trials [51]. If necrosis develops, continuation of
these medications is recommended with the addition of
clodronate to stimulate new bone formation [56]. As nec-
rotic bone cannot be regained, the goal of treatment is pre-
vention of progression, pain control, and management of
secondary infection in hard and soft tissues (osteomyelitis,
cellulitis). Surgical management with local sequestrectomy
or vascularized tissue transfer may be needed [57].
Post treatment fibrosis is best managed by early recog-
nition and physical therapy. Pentoxifylline and vitamin E
has been suggested [58].
Recurrent or second primary oral malignancy is a known
risk and people with prior upper aerodigestive tract cancer
are the highest risk population for a post-treatment malig-
nant lesion. Post-radiation mucosal changes can make de-
tection of early changes difficult, and the potentially
delayed healing in the high dose radiation fields make de-
termination to biopsy more challenging.
Speech and swallow therapists and nutrition/dietary
instruction are important aspects of care in the HNC pa-
tient, and these professionals are important part of the
multidisciplinary HNC team.
Conclusion
The number of HNC survivors has increased, due
mostly to change in risk factors for cancer (HPV), and
advances in cancer therapeutics and supportive care.
This growing population requires specialized oral care
by personnel trained in managing the intricacies of these
complex patients. Oncologists and dentists must collab-
orate to optimize care, as well as to increase knowledge
of preventive and therapeutic options for oral health
maintenance, oral cancer detection and suitable referral
conditions with pathways. The oncology team should in-
clude dental professionals specialized in head and neck
cancer survivor management, which will contribute to
better oral complication prevention, detection, and treat-
ment, and an improved quality of life.
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